Arch Therapeutics, Inc. (ARTH)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Arch Therapeutics, Inc. (ARTH) trades at $0.00 with AI Score 61/100 (Grade B+). Arch Therapeutics, Inc. is a biotechnology company focused on developing innovative wound management solutions. Market cap: $444, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for ARTH: ARTH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ARTH against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ARTH: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Arch Therapeutics, Inc. (ARTH) Healthcare & Pipeline Overview
Arch Therapeutics, Inc. leverages its proprietary AC5 self-assembling technology to develop advanced wound management solutions, addressing critical needs in surgical and trauma care markets with a focus on innovative hemostatic products.
What Is the Investment Thesis for ARTH?
Arch Therapeutics, Inc. presents a unique investment thesis driven by its proprietary AC5 technology, which offers significant advantages in wound management. The company is targeting a growing market, with the global advanced wound care market projected to reach approximately $20 billion by 2027, driven by increasing surgical procedures and chronic wound prevalence. The AC5 product line, including the advanced wound system and topical hemostat, is positioned to capture market share through its innovative approach to wound healing. However, potential risks include the company's negative profit margin of -9221.4% and gross margin of -3.2%, which highlight the financial challenges it faces. The company's ability to secure additional funding and navigate regulatory pathways will be critical in determining its future growth trajectory. Overall, Arch Therapeutics' focus on advanced wound care solutions, combined with the growing market demand, presents a compelling case for potential value creation.
Based on FMP financials and quantitative analysis
ARTH Key Highlights
- Market Cap: $0.00B, indicating the company's current valuation in the market.
- Profit Margin: -9221.4%, reflecting significant operational challenges.
- Gross Margin: -3.2%, highlighting the need for improved cost management.
- Beta: 4.03, indicating high volatility compared to the market.
- No dividend yield, as the company is reinvesting in growth initiatives.
Who Are ARTH's Competitors?
ARTH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings, Inc. | $9.18 | -0.81% | $115.01M | — |
| APDN Applied DNA Sciences, Inc. | $5.62 | +31.62% | $7.26M | 46 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| IVBXF Innovent Biologics, Inc. | $11.39 | +3.02% | $19.76B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ARTH's Key Strengths?
- Innovative AC5 technology with potential for significant market impact.
- Focused product line addressing specific needs in wound management.
- Experienced leadership team with a clear vision for growth.
What Are ARTH's Weaknesses?
- Small employee base limits operational capacity.
- Negative profit and gross margins indicate financial challenges.
- Limited market presence compared to larger competitors.
What Could Drive ARTH Stock Higher?
- Potential FDA approvals for AC5 products could significantly enhance market presence.
- Continued development of the AC5 technology platform to expand product offerings.
- Strategic partnerships with healthcare providers to increase product adoption.
- Efforts to improve financial performance through cost management initiatives.
- Expansion into international markets to diversify revenue streams.
What Are the Key Risks for ARTH?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- High volatility as indicated by a beta of 4.03, which may affect investor sentiment.
- Financial instability due to negative profit margins and limited cash flow.
- Competitive pressures from larger biotechnology firms with established products.
- Regulatory hurdles that could delay product launches and market entry.
- Dependence on a small workforce may limit operational scalability.
What Are the Growth Opportunities for ARTH?
- Growth opportunity 1: The global advanced wound care market is projected to reach $20 billion by 2027, driven by an increase in surgical procedures and chronic wound cases. Arch Therapeutics can leverage its AC5 technology to capture a share of this expanding market, particularly in the management of complex wounds.
- Growth opportunity 2: With the rise in outpatient surgical procedures, the demand for effective wound management solutions is increasing. Arch Therapeutics' products, designed for rapid hemostasis and wound healing, are well-positioned to meet this growing need, potentially increasing market penetration in outpatient settings.
- Growth opportunity 3: The company's focus on regulatory approvals for its AC5 products can open new markets and increase adoption rates. Successful completion of clinical trials and subsequent FDA approvals could lead to significant revenue growth, as healthcare providers seek innovative solutions for wound management.
- Growth opportunity 4: Partnerships with healthcare providers and hospitals can enhance Arch Therapeutics' market presence. By collaborating with key stakeholders in the healthcare sector, the company can drive awareness and adoption of its products, ultimately leading to increased sales and market share.
- Growth opportunity 5: Expanding into international markets presents a significant opportunity for Arch Therapeutics. As global healthcare systems evolve, the demand for advanced wound care products is expected to rise, allowing the company to explore new revenue streams and diversify its customer base.
What Opportunities Does ARTH Have?
- Growing global advanced wound care market presents expansion potential.
- Increasing demand for outpatient surgical procedures enhances product relevance.
- Potential for strategic partnerships to boost market penetration.
What Threats Does ARTH Face?
- Intense competition from established biotechnology firms.
- Regulatory challenges in gaining product approvals.
- Market volatility affecting funding and operational stability.
What Are ARTH's Competitive Advantages?
- Proprietary AC5 self-assembling technology provides a competitive edge.
- Focus on innovative solutions that address unmet needs in wound management.
- Strong potential for intellectual property protection through patents.
- Niche market positioning in the advanced wound care sector.
- Ability to adapt to evolving healthcare trends and regulatory requirements.
What Does ARTH Do?
Founded in 2006, Arch Therapeutics, Inc. is a biotechnology firm headquartered in Framingham, Massachusetts. The company specializes in developing and marketing innovative products that utilize its proprietary AC5 self-assembling technology platform. This technology is designed to effectively stop bleeding and control leaking, making it particularly valuable in surgical, trauma, and interventional care settings. Arch Therapeutics' flagship products, the AC5 advanced wound system and the AC5 topical hemostat, are specifically engineered for skin applications, targeting the management of complicated chronic wounds and acute surgical wounds. The company operates within the highly competitive biotechnology industry, where it seeks to carve out a niche by focusing on advanced wound care solutions that enhance patient outcomes. With a small team of eight employees, Arch Therapeutics is positioned to innovate within the healthcare sector, aiming to improve the efficiency and effectiveness of wound management practices. Over the years, the company has navigated various challenges inherent in biotechnology, including regulatory hurdles and market competition, while striving to establish a strong foothold in the evolving landscape of medical technology.
What Products and Services Does ARTH Offer?
- Develops advanced wound management products using proprietary AC5 technology.
- Offers solutions for stopping bleeding and controlling leaking during surgical procedures.
- Markets AC5 advanced wound system and AC5 topical hemostat for skin applications.
- Focuses on managing complicated chronic wounds and acute surgical wounds.
- Operates primarily in the United States healthcare market.
- Aims to improve patient outcomes through innovative wound care solutions.
How Does ARTH Make Money?
- Generates revenue by selling advanced wound care products to healthcare providers.
- Focuses on developing proprietary technologies to enhance product effectiveness.
- Engages in research and development to innovate and expand product offerings.
- Seeks partnerships with hospitals and clinics to promote product adoption.
- Explores opportunities for international market expansion to increase sales.
What Industry Does ARTH Operate In?
The biotechnology industry is characterized by rapid innovation and significant investment in research and development. The advanced wound care market, in particular, is experiencing robust growth, driven by an aging population, increasing incidence of chronic wounds, and advancements in medical technology. Arch Therapeutics, Inc. operates within this dynamic environment, competing against established players and emerging startups. The market is expected to expand significantly, with estimates suggesting a growth rate of approximately 6% annually over the next five years. Arch Therapeutics aims to differentiate itself through its proprietary technology, which addresses critical gaps in current wound management practices.
Who Are ARTH's Key Customers?
- Hospitals and surgical centers requiring advanced wound management solutions.
- Healthcare providers looking for effective hemostatic products.
- Patients with chronic wounds or those undergoing surgical procedures.
- Medical professionals in trauma and interventional care settings.
- Healthcare institutions focused on improving patient outcomes.
Arch Therapeutics, Inc. Financial Trajectory
Arch Therapeutics, Inc. (ARTH) reported $31K in revenue for Q2 2024, a decline of 3.0% compared to the prior quarter. The company recorded a net loss of $5.7M, with diluted EPS of $-1.44.
Company Profile
Arch Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Framingham, US. The company is led by CEO Terrence W. Norchi. ARTH has traded publicly since 2013.
How Arch Therapeutics, Inc. Is Valued
Arch Therapeutics, Inc. carries a market capitalization of 444, placing it in the micro-cap category. Relative to its peer group, ARTH's quantitative score of 61/100 is roughly in line with the peer average of 70/100.
ROE 119%Key Financial Metrics
Return on equity for Arch Therapeutics, Inc. stands at 119.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.21 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 3/9Financial Health
Arch Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
FY2026 estForward Outlook
Wall Street analysts project Arch Therapeutics, Inc. revenue of about $328.9M for fiscal 2026, with EPS near $15.13.
ARTH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying could signal confidence in ARTH's future prospects, suggesting those closest to the company see value.
- The social trading community seems optimistic about ARTH's potential applications in wound care, fueling positive sentiment.
- Perception of ARTH as an innovator in the medical device space may attract further investment and partnerships.
- Bullish community members highlight the potential market size for ARTH's products, indicating significant growth opportunities.
Bear Case
- Limited news flow around ARTH in the last 30 days might indicate a lack of significant progress or upcoming catalysts.
- Bearish community members express concern about the time it's taking for ARTH to achieve commercial success.
- Market perception of small-cap biotech companies can be volatile, leading to unpredictable stock movements.
- The wound care market is competitive, and ARTH faces established players, which could hinder market penetration.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2024 | $30,913 | -$6M | -$1.44 |
| Q1 2024 | $31,866 | -$1M | -$0.33 |
Based on FMP financials and quantitative analysis
ARTH Latest News
-
USA Rare Earth Hits Speed Bump As It Unlocks $1.6 Billion In U.S. Funding
Investor's Business Daily · Jun 3, 2026
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Friday
· Oct 25, 2019
ARTH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ARTH.
Price Targets
Wall Street price target analysis for ARTH.
ARTH MoonshotScore
What does this score mean?
The MoonshotScore rates ARTH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Terrence W. Norchi
CEO
Terrence W. Norchi has a robust background in biotechnology and healthcare management. He has held various leadership roles in the industry, focusing on product development and commercialization strategies. Norchi's educational credentials include a degree in business and extensive experience in navigating complex regulatory environments.
Track Record: Under Norchi's leadership, Arch Therapeutics has made significant strides in product development and market positioning. His strategic decisions have aimed at enhancing the company's visibility in the advanced wound care sector, paving the way for potential growth opportunities.
ARTH OTC Market Information
The OTC Other tier represents companies that trade on the over-the-counter market but do not meet the stricter listing requirements of major exchanges like NYSE or NASDAQ. This tier often includes smaller companies with limited financial resources and visibility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosures may hinder transparency for investors.
- Lower trading volume can lead to higher price volatility.
- Potential for regulatory scrutiny affecting operations and market access.
- Verify the company's financial health through available reports.
- Assess the competitive landscape and market positioning.
- Review the management team's experience and track record.
- Investigate any ongoing regulatory issues or challenges.
- Examine product pipeline and potential for future approvals.
- Established company with a founding date of 2006.
- Presence of a proprietary technology platform.
- Engagement in product development and clinical trials.
What Investors Ask About Arch Therapeutics, Inc. (ARTH) — Healthcare
What does Arch Therapeutics, Inc. do?
Arch Therapeutics, Inc. is a biotechnology company focused on developing advanced wound management solutions. Utilizing its proprietary AC5 self-assembling technology, the company creates products designed to stop bleeding and manage wounds effectively during surgical and trauma care. Its flagship products include the AC5 advanced wound system and AC5 topical hemostat, aimed at improving patient outcomes in various healthcare settings.
What are the main risks for ARTH?
Arch Therapeutics faces several risks, including high volatility indicated by a beta of 4.03, which could impact investor confidence. Additionally, the company has a negative profit margin of -9221.4%, raising concerns about financial sustainability. Competitive pressures from larger firms and potential regulatory hurdles may also pose significant challenges, affecting the company's ability to launch products and gain market share.
How does Arch Therapeutics, Inc. manage patent expiration risks?
Arch Therapeutics mitigates patent expiration risks by focusing on innovation and developing proprietary technologies that can be patented. By continuously advancing its AC5 technology and expanding its product pipeline, the company aims to maintain a competitive edge in the market. Additionally, effective lifecycle management strategies are employed to maximize the value of existing patents while exploring new therapeutic applications.
What are the key factors to evaluate for ARTH?
Arch Therapeutics, Inc. (ARTH) holds an AI score of 61/100 (moderate). Not financial advice.
How frequently does ARTH data refresh on this page?
ARTH prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ARTH's recent stock price performance?
Arch Therapeutics, Inc. (ARTH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative AC5 technology with potential for significant market impact. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ARTH overvalued or undervalued right now?
Valuing Arch Therapeutics, Inc. (ARTH) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ARTH?
Before investing in Arch Therapeutics, Inc. (ARTH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available due to OTC classification and small company size.